Prostate cancer screening: What we have learned from the PLCO and ERSPC trials

Jeffrey La Rochelle, Christopher Amling

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Two large randomized trials on prostate cancer screening have recently reported their 10-year results with somewhat differing conclusions. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) study found a slightly higher risk of a prostate cancer diagnosis in the screening cohort, but no cancer-specific survival advantage was seen for this group. However, the study had widespread screening contamination in the control arm that significantly weakens the study's ability to reach a valid conclusion about the benefits of screening. The European Randomized Study of Screening in Prostate Cancer (ERSPC) was less affected by screening contamination of the control arm, and a cancer-specific survival benefit for the screening arm was seen by 7-8 years (RR, 0.70-0.80). Based on these studies, it is reasonable to conclude that there is a survival benefit for screening, but it may not extend to older men (>75 years) who have undergone prior screening.

Original languageEnglish (US)
Pages (from-to)198-201
Number of pages4
JournalCurrent Urology Reports
Volume11
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Early Detection of Cancer
Ovarian Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Survival
Neoplasms

Keywords

  • Prostate cancer
  • Prostate-specific antigen
  • Randomized studies
  • Screening

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Prostate cancer screening : What we have learned from the PLCO and ERSPC trials. / La Rochelle, Jeffrey; Amling, Christopher.

In: Current Urology Reports, Vol. 11, No. 3, 05.2010, p. 198-201.

Research output: Contribution to journalArticle

@article{342a52709c534bd39be25fcb2c824812,
title = "Prostate cancer screening: What we have learned from the PLCO and ERSPC trials",
abstract = "Two large randomized trials on prostate cancer screening have recently reported their 10-year results with somewhat differing conclusions. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) study found a slightly higher risk of a prostate cancer diagnosis in the screening cohort, but no cancer-specific survival advantage was seen for this group. However, the study had widespread screening contamination in the control arm that significantly weakens the study's ability to reach a valid conclusion about the benefits of screening. The European Randomized Study of Screening in Prostate Cancer (ERSPC) was less affected by screening contamination of the control arm, and a cancer-specific survival benefit for the screening arm was seen by 7-8 years (RR, 0.70-0.80). Based on these studies, it is reasonable to conclude that there is a survival benefit for screening, but it may not extend to older men (>75 years) who have undergone prior screening.",
keywords = "Prostate cancer, Prostate-specific antigen, Randomized studies, Screening",
author = "{La Rochelle}, Jeffrey and Christopher Amling",
year = "2010",
month = "5",
doi = "10.1007/s11934-010-0109-5",
language = "English (US)",
volume = "11",
pages = "198--201",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Prostate cancer screening

T2 - What we have learned from the PLCO and ERSPC trials

AU - La Rochelle, Jeffrey

AU - Amling, Christopher

PY - 2010/5

Y1 - 2010/5

N2 - Two large randomized trials on prostate cancer screening have recently reported their 10-year results with somewhat differing conclusions. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) study found a slightly higher risk of a prostate cancer diagnosis in the screening cohort, but no cancer-specific survival advantage was seen for this group. However, the study had widespread screening contamination in the control arm that significantly weakens the study's ability to reach a valid conclusion about the benefits of screening. The European Randomized Study of Screening in Prostate Cancer (ERSPC) was less affected by screening contamination of the control arm, and a cancer-specific survival benefit for the screening arm was seen by 7-8 years (RR, 0.70-0.80). Based on these studies, it is reasonable to conclude that there is a survival benefit for screening, but it may not extend to older men (>75 years) who have undergone prior screening.

AB - Two large randomized trials on prostate cancer screening have recently reported their 10-year results with somewhat differing conclusions. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) study found a slightly higher risk of a prostate cancer diagnosis in the screening cohort, but no cancer-specific survival advantage was seen for this group. However, the study had widespread screening contamination in the control arm that significantly weakens the study's ability to reach a valid conclusion about the benefits of screening. The European Randomized Study of Screening in Prostate Cancer (ERSPC) was less affected by screening contamination of the control arm, and a cancer-specific survival benefit for the screening arm was seen by 7-8 years (RR, 0.70-0.80). Based on these studies, it is reasonable to conclude that there is a survival benefit for screening, but it may not extend to older men (>75 years) who have undergone prior screening.

KW - Prostate cancer

KW - Prostate-specific antigen

KW - Randomized studies

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=77952236601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952236601&partnerID=8YFLogxK

U2 - 10.1007/s11934-010-0109-5

DO - 10.1007/s11934-010-0109-5

M3 - Article

C2 - 20425627

AN - SCOPUS:77952236601

VL - 11

SP - 198

EP - 201

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 3

ER -